Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Evolus, Inc. - Common Stock (NQ:EOLS)

5.200 -0.460 (-8.13%)
Streaming Delayed Price Updated: 1:14 PM EST, Mar 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 753,872
Open 5.680
Bid (Size) 5.200 (400)
Ask (Size) 5.210 (700)
Prev. Close 5.660
Today's Range 5.170 - 5.680
52wk Range 4.091 - 14.60
Shares Outstanding 54,576,156
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Why Evolus Stock Soared Today ↗
The promise of a more youthful appearance is a powerful draw. 
Via The Motley Fool
What's going on in today's session ↗
Via Chartmill

Performance

YTD
-22.6%
-22.6%
1 Month
+10.6%
+10.6%
3 Month
-23.6%
-23.6%
6 Month
-30.8%
-30.8%
1 Year
-63.3%
-63.3%

More News

Read More
Gapping stocks in Wednesday's session ↗
Via Chartmill
News headline image
Evolus (EOLS) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings World Trade
Evolus Inc (NASDAQ:EOLS) Reports Q4 2025 Earnings Beat and Path to 2026 Profitability ↗
Via Chartmill
Topics Earnings
News headline image
Earnings Scheduled For November 5, 2025 ↗
Via Benzinga
These stocks are moving in today's after hours session ↗
Via Chartmill
News headline image
Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026
From Evolus
Via Business Wire
News headline image
Evolus to Participate in The Leerink Partners Global Healthcare Conference
From Evolus
Via Business Wire
News headline image
Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026
From Evolus
Via Business Wire
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
News headline image
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue
From Evolus
Via Business Wire
News headline image
This Biotech Is Up 194% in a Year but One Investor Took Millions Off the Table ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
News headline image
Evolus (EOLS) Q3 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings World Trade
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Via Benzinga
News headline image
Evolus Reports Third Quarter 2025 Financial Results
From Evolus
Via Business Wire
News headline image
Evolus to Participate in 2025 Stifel Healthcare Conference
From Evolus
Via Business Wire
News headline image
Evolus to Report Third Quarter Financial Results on November 5, 2025
From Evolus
Via Business Wire
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
News headline image
Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
News headline image
Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer
From Evolus
Via Business Wire
News headline image
Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp
From Evolus
Via Business Wire
News headline image
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product
From Evolus
Via Business Wire

Frequently Asked Questions

Is Evolus, Inc. - Common Stock publicly traded?
Yes, Evolus, Inc. - Common Stock is publicly traded.
What exchange does Evolus, Inc. - Common Stock trade on?
Evolus, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Evolus, Inc. - Common Stock?
The ticker symbol for Evolus, Inc. - Common Stock is EOLS on the Nasdaq Stock Market
What is the current price of Evolus, Inc. - Common Stock?
The current price of Evolus, Inc. - Common Stock is 5.200
When was Evolus, Inc. - Common Stock last traded?
The last trade of Evolus, Inc. - Common Stock was at 03/06/26 01:14 PM ET
What is the market capitalization of Evolus, Inc. - Common Stock?
The market capitalization of Evolus, Inc. - Common Stock is 283.80M
How many shares of Evolus, Inc. - Common Stock are outstanding?
Evolus, Inc. - Common Stock has 284M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.